Skip to main content
Samra Turajlic on Muck Rack

Samra Turajlic

As seen in: Nature, Flipboard, BioRxiv, Cell Press, The Lancet, European Urology, UroToday, Inkl, European Journal of Cancer
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Samra

Contact Samra, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Beyond the Primary Tumour: Rethinking Biomarker Strategies in Recurrent Renal Cell Carcinoma

|
By Lewis Au, Samra Turajlic
| European Urology Verified
Get full text access Log in, subscribe or purchase for full access. References 1. Choueiri, T.K. ∙ Tomczak, P. ∙ Park, S.H. ... Overall survival with adjuvant pembrolizumab in renal-cell carcinoma N Engl J Med. 2024; 390:1359-1371 2. Grünwald, V. ∙ Bex, A. ∙ Rottey, S. ... Current status of adjuvant immunotherapy and relapse management in renal cell carcinoma: insights from a European Delphi study Eur J Cancer. 2025; 225, 115569 3. Choueiri, T.K. ∙ Motzer, R.J. ∙ Karam, J.A. ...
Open in Who Shared Issue with article?

Immunotherapy drug target identification using machine learning and patient-derived tumour explant validation

|
By Marcellus Augustine, Nuno Rocha Nené, Hongchang Fu, Christopher L. Pinder, Lorena Ligammari, Alexander Simpson, Irene Sanz-Fernández, Krupa Thakkar, Danwen Qian, Evelyn Fitzsimons, Benjamin S. Simpson, Roberto Vendramin, Andrea Castro, Samra Turajlic, Sergio A Quezada, Nicholas McGranahan, Chris Watkins, Charles Swanton, Kevin Litchfield, Heather Niederer
| Nature Verified
Abstract Immunotherapy has revolutionized cancer treatment, yet only a minority of individuals respond clinically, necessitating alternative strategies that can benefit these patients. Novel immuno-oncology targets may achieve this through bypassing resistance mechanisms to standard therapies. We introduce Mining Immunotherapy Drug tArgetS (MIDAS), a multimodal graph neural network system for immuno-oncology target discovery.
Open in Who Shared Issue with article?

Immunometabolic gatekeeping: How tissue metabolism conditions tumor immunity

|
By Naomi Iris van den Berg, Matouš Elphick, Kevin P. Mulder, Omar Bouricha, Omid Sadeghi-Alavijeh, XIAO FU, Samra Turajlic
| Cell Press Verified
Get full text access Log in, subscribe or purchase for full access. References 1. Sarver, D.C. ∙ Saqib, M. ∙ Chen, F. ... Mitochondrial respiration atlas reveals differential changes in mitochondrial function across sex and age eLife. 2024; 13:RP96926 2. Bruni, D. ∙ Angell, H.K. ∙ Galon, J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy Nat. Rev. Cancer. 2020; 20:662-680 3. Zuo, S. ∙ Wei, M. ∙ Wang, S. ...
Open in Who Shared Issue with article?
See all 34 articles